Current review of the comorbidity of affective, anxiety, and substance use disorders

Current Opinion in Psychiatry

Volumn 16, Issue 3, 2003, Pages 261-270

  Myrick, Hugh ^a   Brady, Kathleen ^a  

^a RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Anxiety disorders; Co occurring disorders; Dual diagnosis; Mood disorders

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CLONAZEPAM; CLONIDINE; FLUOXETINE; GABAPENTIN; IMIPRAMINE; LITHIUM; LORAZEPAM; MONOAMINE OXIDASE INHIBITOR; ONDANSETRON; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE;

ANXIETY DISORDER; BEHAVIOR THERAPY; BIPOLAR DISORDER; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DRUG DEPENDENCE; GENERALIZED ANXIETY DISORDER; HUMAN; MOOD DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; PREVALENCE; PROGNOSIS; PSYCHOTHERAPY; REVIEW; SOCIAL PHOBIA; SYMPTOMATOLOGY; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

EID: 0037728729     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yco.0000069080.26384.d8     Document Type: Review

References (86)

1. Reiger DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA 1990; 264:2511-2518.
2. Kessler RC, Nelson CB, McGonagle KA, et al. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry 1996; 66:17-31.
3. Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol 1995; 56:423-432.
4. Teitelbaum LM, Carey KB. Temporal stability of alcohol screening measures in a psychiatric setting. Psychol Addict Behav 2000; 14:401-404.
5. Cocco KM, Carey KB. Psychometric properties of the Drug Abuse Screening Test in psychiatric outpatients. Psychol Assess 1998; 10:408-414.
6. Maisto SA, Carey MP, Carey KB, et al. Use of the AUDIT and the DAST-10 to identify alcohol and drug use disorders among adults with a severe and persistent mental illness. Psychol Assess 2000; 12:186-192.
7. Skipsey K, Burleson JA, Kranzler HR. Utility of the AUDIT for identification of hazardous or harmful drinking in drug-dependent patients. Drug Alcohol Depend 1997; 45:157-163.
8. Franken IH, Hendriks VM. Screening and diagnosis of anxiety and mood disorders in substance abuse patients. Am J Addict 2001; 10:30-39.
9. Kranzler HR, Kadden RM, Babor TF, et al. Validity of the SCID in substance abuse patients. Addiction 1996; 91:859-868.
10. Hasin DS, Trautman KD, Miele GM, et al. Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. Am J Psychiatry 1996; 153:1195-1201.
11. Barlow DH, Lehman CL. Advances in the psychosocial treatment of anxiety disorders: implications for national health care. Arch Gen Psychiatry 1996; 53:727-735.
12. Anton RF, Moak DH, Waid LR, et al. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 1999; 156:1758-1764.
13. Markowitz J, Weissman M, Ouellette R. Quality of life in panic disorder. Arch Gen Psychiatry 1989; 46:984-992.
14. Kushner MG, Sher KJ, Beitman BD. The relation between alcohol problems and the anxiety disorders. Am J Psychiatry 1990; 147:685-695.
15. Milby JB, Sims MK, Khuder S, et al. Psychiatric comorbidity: prevalence in methadone maintenance treatment. Am J Drug Alcohol Abuse 1996; 22:95-107.
16. Rosen MI, Kosten T. Cocaine-associated panic attacks in methadone-maintained patients. Am J Drug Alcohol Abuse 1992; 18:57-62.
17. Cox DJ, Ballenger JC, Laraia M, et al. Different rates of improvement of different symptoms in combined pharmacological and behavioral treatment of agoraphobia. J Behav Ther Exp Psychiatry 1988; 19:119-126.
18. Rounsaville BJ, Anton SF, Carroll K, et al. Psychiatric diagnoses of treatment-seeking cocaine abusers. Arch Gen Psychiatry 1991; 48:43-51.
19. Moran C. Depersonalization and agoraphobia associated with marijuana use. Br J Med Psychol 1986; 59:187-196.
20. Aronson TA, Craig TJ. Cocaine precipitation of panic disorder. Am J Psychiatry 1986; 143:643-645.
21. Louie AK, Lannon RA, Ketter TA. Treatment of cocaine-induced panic disorder. Am J Psychiatry 1989; 146:40-44.
22. Price WA, Giannini AJ. Phencyclidine and 'crack'-precipitated panic disorder. Am J Psychiatry 1987; 144:686-687.
23. Lydiard RB, Brawman-Mintzer O, Ballenger JC. Recent developments in the psychopharmacology of anxiety disorders. J Consult Clin Psychol 1996; 64:660-668.
24. den Boer JA, Westenberg HG, Kamerbeek WD, et al. Effect of serotonin uptake inhibitors in anxiety disorders: a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 1987; 2:21-32.
25. Gorelick DA. Serotonin uptake blockers and the treatment of alcoholism. Recent Dev Alcohol 1989; 7:262-281.
26. Pettinati HM, Volpicelli JR, Kranzler HR, et al. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res 2000; 24:1041-1049.
27. Posternak MA, Mueller TI. Assessing the risks and benefits of benzodiazepines for anxiety disorders in patients with a history of substance abuse or dependence. Am J Addict 2001; 10:48-68.
28. Malcolm R, Myrick H, Roberts J, et al. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Internal Med 2002; 17:1-7.
29. Post RM. Cocaine psychoses: a continuum model. Am J Psychiatry 1975; 132:225-231.
30. Barlow DH. Anxiety and its disorders: the nature and treatment of anxiety and panic. New York: Guilford Press; 1988.
31. Jansson L, Ost L-G. Behavioral treatments for agoraphobia: an evaluative review. Clin Psychol Rev 1982; 2:311-336.
32. Chambless DL, Cherney J, Caputo GC. Anxiety disorders and alcoholism: a study with inpatient alcoholics. J Anxiety Disord 1987; 18:29-40.
33. Massion AO, Warshaw MG, Keller MB. Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. Am J Psychiatry 1993; 150:600-607.
34. Milby JB, Sims MK, Khuder S, et al. Psychiatric comorbidity: prevalence in methadone maintenance treatment. Am J Drug Alcohol Abuse 1996; 22:95-107.
35. Kranzler HR, Burleson JA, Del Boca FK, et al. Buspirone treatment of anxious alcoholics: a placebo-controlled trial. Arch Gen Psychiatry 1994; 51:720-731.
36. Malcolm R, Anton RF, Randall CL, et al. A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res 1992; 16:1007-1013.
37. McRae AL, Sonne SC, Brady, KT. The use of buspirone for the treatment of persistent anxiety in methadone-maintained patients. Am J Addictions; (in press)
38. Blowers C, Cobb J, Mathews A. Generalized anxiety: a controlled treatment study. Behav Res Ther 1987; 25:493-502.
39. Butler G, Fennell M, Robson P, Gelder M. Comparison of behavior therapy and cognitive behavior therapy in the treatment of generalized anxiety disorder. J Consult Clin Psychol 1991; 59:167-175.
40. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8-19.
41. Marshall JR. The diagnosis and treatment of social phobia and alcohol abuse. Bull Menninger Clin 1994; 58:58-66.
42. Myrick DH, Brady KT. Social phobia in cocaine-dependent individuals. Am J Addict 1996; 6:99-104.
43. Thevos AK, Johnston AL, Latham PK, et al. Symptoms of anxiety in inpatient alcoholics with and without DSM-III-R anxiety diagnoses. Alcohol Clin Exp Res 1991; 15:102-161.
44. Heimberg RG, Dodge CS, Hope DA, et al. Cognitive-behavioral group treatment of social phobia: comparison to a credible placebo control. Cognit Ther Res 1990; 14:1-23.
45. Heimberg RG, Salzman DG, Holt DC, Blendell KA. Cognitive-behavioral group treatment for social phobia. Cognit Ther Res 1993; 4:325-339.
46. Lydiard RB, Falsetti SA. Treatment options for social phobia. Psychiatr Ann 1995; 25:570-576.
47. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999; 19:341-348.
48. Randall CL, Johnson MR, Thevos AK, et al. Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depress Anxiety 2001; 14:255-462.
49. Kasvikis YG, Tsakiris F, Marks IM. Past history of anorexia nervosa in women with obsessive-compulsive disorder. Int J Eat Disorders 1986; 5:1069-1075.
50. Crum RM, Anthony JC. Cocaine use and other suspected risk factors for obsessive compulsive disorder: a prospective study with data from the Epidemiologic Catchment Area surveys. Drug Alcohol Depend 1993; 31:281-295.
51. Brady KT, Lydiard RB, Malcolm R, Ballenger JC. Cocaine-induced psychosis. J Clin Psychiatry 1991; 52:509-512.
52. Senjo M. Obsessive-compulsive disorder in people that abuse codeine. Acta Psychiatr Scand 1989; 79:619-620.
53. Leonard HL, Rapoport JL. Relief of obsessive-compulsive symptoms by LSD and psilocin. Am J Psychiatry 1987; 144:1239-1240.
54. Myrick DH, Brady KT. Social phobia in cocaine-dependent individuals. Am J Addict 1996; 6:99-104.
55. Fals-Stewart W, Marks AP, Schafer J. A comparison of behavioral group therapy and individual behavior therapy in treating obsessive-compulsive disorder. J Nerv Ment Dis 1993; 181:189-193.
56. van Oppen P, Arntz A. Cognitive therapy for obsessive-compulsive disorder. Behav Res Ther 1994; 32:79-87.
57. Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1995; 52:1048-1060.
58. Cottler L, Compton W, Mager D, et al. Posttraumatic stress disorder among substance users from the general population. Am J Psychiatry 1992; 149:664-670.
59. Grice DE, Brady KT, Dustan LR, et al. Sexual and physical assault history and posttraumatic stress disorder in substance-dependent individuals. Am J Addict 1995; 4:1-9.
60. Triffleman E, Marmer C, Delucchi K. Childhood trauma and posttraumatic stress disorder in substance abuse inpatients. J Nerv Mental Dis 1995; 183:172-176.
61. Dansky BS, Brady KT, Roberts JT. Post-traumatic stress disorder and substance abuse: Empirical findings and clinical issues. Subst Abus 1994; 15:247-257.
62. Jacobsen LK, Southwick SM, Kosten TR. Substance use disorders in patients with posttraumatic stress disorder: a review of the literature. Am J Psychiatry 2001; 158:1184-1190.
63. Davidson J. Drug therapy of post-traumatic stress disorder. Br J Psychiatry 1992; 160:309-314.
64. Brady KT, Killeen TK, Brewerton T, Lucerini S. Comorbidity of psychiatric disorders and posttraumatic stress disorder. J Clin Psychiatry 2000; 61:22-32.
65. Davidson JR, Rothbaum BO, van der Kolk BA, et al. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 2001; 58:485-492.
66. Marshall RD, Beebe KL, Oldham M, Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 2001; 158:1982-1988.
67. van der Kolk BA, Dreyfuss D, Michaels M, et al. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 1994; 55:517-522.
68. Brady KT, Sonne SC, Roberts JM. Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. J Clin Psychiatry 1995; 56:502-505.
69. Najavits LM, Weiss RD, Liese BS. Group cognitive-behavioral therapy for women with PTSD and substance use disorder. J Subst Abuse Treat 1996; 13:13-22.
70. Brady KT, Dansky BS, Back SE, et al. Exposure therapy in the treatment of PTSD among cocaine-dependent individuals: preliminary findings. J Subst Abuse Treat 2001; 21:47-54.
71. Brown WE, Schuckit M. Changes in depression among abstinent alcoholics. J Stud Alcohol 1988; 49:412-417.
72. Brady KT, Sonne SC. The role of stress in alcohol use, alcoholism treatment, and relapse. Alcohol Res Health 1999; 23:263-271.
73. Brooner RK, King VL, Kidorf M, et al. Psychiatric and substance comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry 1997; 54:71-80.
74. Mason BJ, Kocsis JH, Ritvo EC, et al. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA 1996; 275:761-767.
75. McGrath PJ, Nunes EV, Stewart JW, et al. Imipramine treatment of alcoholics with primary depression: a placebo-controlled clinical trial. Arch Gen Psychiatry 1996; 53:232-240.
76. Gorelick DA. Serotonin uptake blockers and the treatment of alcoholism. Recent Dev Alcohol 1989; 7:267-281.
77. Cornelius JR, Salloum IM, Ehler JG, et al. Fluoxetine in depressed alcoholics: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997; 54:700-705.
78. Nunes EV, Quitkin FM, Donoval SJ, et al. Imipramine treatment of opiate-dependent patients with depressive disorders. Arch Gen Psychiatry 1998; 55:153-160.
79. Rao S, Ziedonis D, Kosten T. The pharmacotherapy of cocaine dependence. Psychiatr Ann 1995; 25:363-368.
80. Schmitz JM, Averill P, Stotts AL, et al. Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. Drug Alcohol Depend 2001; 63:207-214. This well-designed, controlled trial presents negative data concerning the use of fluoxetine in the treatment of co-morbid cocaine dependence and major depression.
81. Petrakis I, Carroll KM, Nich C, et al. Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug Alcohol Depend 1998; 50:221-226.
82. Bowden CL. Predictors of response to divalproex and lithium. J Clin Psychiatry 1995; 56:25-30.
83. Weiss RD, Greenfield SF, Najavits LM, et al. Medication compliance among patients with bipolar disorder and substance use disorder. J Clin Psychiatry 1998; 59:172-174.
84. Brady KT, Myrick H, Henderson S, Coffey SF. The use of divalproex in alcohol relapse prevention: a pilot study. Drug Alcohol Depend 2002; 67:323-330.
85. Brown RA, Evans DM, Miller IW, et al. Cognitive-behavioral treatment for depression in alcoholism. J Consult Clin Psychol 1997; 65:715-726.
86. Weiss RD, Griffin ML, Greenfield SF, et al. Group therapy for patients with bipolar disorder and substance dependence: results of a pilot study. J Clin Psychiatry 2000; 61:361-367.